Research programme: sialidase inhibitors - OncoImmune
Latest Information Update: 22 Feb 2016
At a glance
- Originator OncoImmune
- Class Small molecules
- Mechanism of Action Neuraminidase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Sepsis
Most Recent Events
- 22 Feb 2016 Preclinical trials in Sepsis (Prevention) in USA (unspecified route)